Effect of Reduction of Inflammatory Status on Glucose Metabolism in Overweight Men
Information source: TNO Quality of Life
Information obtained from ClinicalTrials.gov on March 24, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Overweight; Obesity; Inflammation
Intervention: Diclofenac (Drug)
Sponsored by: TNO Quality of Life
Official(s) and/or principal investigator(s):
Trinette van Vliet, PhD, Principal Investigator, Affiliation: TNO Quality of Life, Location Zeist
Overweight increases the risk to develop chronic diseases including type-2 diabetes and
cardiovascular disease. The low-grade inflammatory status often seen in overweight subjects
is thought to play an important role in disease development.
The purpose of this study is to determine the role of inflammation on glucose metabolism and
insulin resistance. In this study the effect of the anti-inflammatory treatment diclofenac on
markers of inflammation and on parameters of glucose metabolism will be studied.
Official title: Relation Between Reduction of the Inflammatory Status and Glucose Metabolism in Healthy Overweight Men
Study design: Randomized, Double-Blind, Placebo Control, Parallel Assignment
Minimum age: 18 Years.
Maximum age: 60 Years.
- Body Mass Index (BMI): 25. 1 – 32. 0 kg/m2
- Normal Dutch eating habits
- diabetes, cardiovascular disease or hypertension
- Not suitable to receive diclofenac treatment
- Extreme physical activity (more than 6 hours/week)
- Reported slimming or medically prescribed diet
Locations and Contacts
TNO Quality of Life, Zeist 3700 AJ, Netherlands
Starting date: June 2005
Ending date: July 2005
Last updated: October 10, 2006